Low sensitivity of the careHPV™ Assay for detection of Oncogenic Human Papillomavirus in cervical samples from HIV-infected and HIV-uninfected Kenyan women
Article Sidebar
Main Article Content
Abstract
Background: Human papillomavirus (HPV) infection causes cervical cancer (CC), a common malignancy among Kenyan women. New CC screening methods rely on oncogenic HPV (“high-risk”, or HR-HPV) detection, but most have not been evaluated in swabs from Kenyan women.
Methods: HPV typing was performed on 155 cervical swabs from Kenyan women using the Roche Linear Array® (LA) and careHPV™ (careHPV) assays. Detection of 14 oncogenic HPV types in careHPV assay was compared to LA results.
Results: Compared to LA, sensitivity and specificity of careHPV assay was 53.0% and 80.9%, respectively. The sensitivity and specificity of careHPV in swabs from women with cervical dysplasia was 74.1% and 65.2%, respectively. The sensitivity and specificity of careHPV in swabs from HIV-infected women was 55.9% and of 96.4%, respectively. Overall agreements of careHPV assay with LA was substantial.
Conclusion: The results for careHPV assay are promising for oncogenic HPV detection in Kenyan women. The low sensitivity of careHPV for detection of HR-HPV could limit it’s benefit as a screening tool. Thus, a full clinical validation study is highly desirable before the careHPV assay can be accepted for cervical cancer screening.
Article Details
Copyright (c) 2020 Titus M, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30207593
zur Hausen H. Papillomavirus infections--a major cause of human cancers. Biochim Biophys Acta. 1996; 1288: F55-F78. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8876633
Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. J Natl Cancer Inst Monogr. 2003; 31: 3-13. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12807939
Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348: 518-527. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12571259
Cronje HS. Screening for cervical cancer in developing countries. Int J Gynaecol Obstet. 2004; 84: 101-108. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14871510
Vedantham H, Silver MI, Kalpana B, Rekha C, Karuna BP, et al. Determinants of VIA (Visual Inspection of the Cervix After Acetic Acid Application) positivity in cervical cancer screening of women in a peri-urban area in Andhra Pradesh, India. Cancer Epidemiol Biomarkers Prev. 2010; 19: 1373-1380. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913449/
An Y, Shi X, Tang X, Wang Y, Shen F, et al. Aflatoxin B1 Induces Reactive Oxygen Species-Mediated Autophagy and Extracellular Trap Formation in Macrophages. Front Cell Infect Microbiol. 2017; 7: 53. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322174/
Raifu AO, El-Zein M, Sangwa-Lugoma G, Ramanakumar A, Walter SD, et al. Determinants of Cervical Cancer Screening Accuracy for Visual Inspection with Acetic Acid (VIA) and Lugol's Iodine (VILI) Performed by Nurse and Physician. PLoS One. 2017; 12: e0170631. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28107486
El-Zein M, Richardson L, Franco EL. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none. J Clin Virol. 2016; 76 Suppl 1: S62-S68. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26631958
Ying H, Jing F, Fanghui Z, Youlin Q, Yali H. High-risk HPV nucleic acid detection kit-the careHPV test -a new detection method for screening. Sci Rep. 2014; 4: 4704. PubMed https://www.ncbi.nlm.nih.gov/pubmed/24736475
Arney A, Bennett KM. Molecular Diagnostics of Human Papillomavirus. Lab Medicine. 2010; 41: 523-530.
Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005; 191: 182-192. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15609227
Buderer NM. Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity. Acad Emerg Med. 1996; 3: 895-900. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8870764
McGinn T, Wyer PC, Newman TB, Keitz S, Leipzig R, et al. Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic). CMAJ. 2004; 171: 1369-1373. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15557592
Manga MM, Fowotade A, Abdullahi YM, El-Nafaty AU, Adamu DB. Epidemiological patterns of cervical human papillomavirus infection among women presenting for cervical cancer screening in North-Eastern Nigeria. Infect Agent Cancer. 2015; 10: 39. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26435733
Ngou J, Gilham C, Omar T, Goumbri-Lompo O, Doutre S, et al. Comparison of analytical and clinical performances of the digene HC2 HPV DNA assay and the INNO-LiPA HPV genotyping assay for detecting high-risk HPV infection and cervical neoplasia among HIV-positive African women. J Acquir Immune Defic Syndr. 2015; 68: 162-168. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25394189
Segondy M, Kelly H, Magooa MP, Djigma F, Ngou J, et al. Performance of careHPV for detecting high-grade cervical intraepithelial neoplasia among women living with HIV-1 in Burkina Faso and South Africa: HARP study. Br J Cancer. 2016; 115: 425-430. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27434037
Obiri-Yeboah D, Adu-Sarkodie Y, Djigma F, Akakpo K, Aniakwa-Bonsu E, et al. Options in human papillomavirus (HPV) detection for cervical cancer screening: comparison between full genotyping and a rapid qualitative HPV-DNA assay in Ghana. Gynecol Oncol Res Pract. 2017; 4: 5. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28270915